激肽释放酶治疗后精液质量评估。

Evaluation of semen quality following kallikrein treatment.

作者信息

Homonnai Z T, Shilon M, Paz G

出版信息

Gynecol Obstet Invest. 1978;9(2-3):132-8. doi: 10.1159/000300976.

Abstract

30 asthenozoospermic subfertile men were treated parenterally for 30 months with kallikrein. 20 men showed a significant increase in sperm motility, 66% (responders), while the other 10 men, 34% (non-responders), did not respond to this treatment. A striking decrease in sperm concentration (by 32%) was found in most patients. No latent period was found following kallikrein treatment. Thus, semen quality did not differ if examined immediately following the cessation of treatment or a few weeks afterwards. A poor pregnancy rate was recorded, i.e. 20% among the responders and 10% among the non-responders. In conclusion, kallikrein is a useful drug in the treatment of asthenozoospermia only when the sperm concentration is not decreased below the optimal value.

摘要

30名弱精子症不育男性接受了30个月的激肽释放酶非肠道给药治疗。20名男性的精子活力显著提高，占66%（反应者），而另外10名男性，占34%（无反应者），对该治疗无反应。大多数患者的精子浓度显著降低（降低了32%）。激肽释放酶治疗后未发现潜伏期。因此，在治疗停止后立即检查或几周后检查，精液质量没有差异。妊娠率较低，即反应者中为20%，无反应者中为10%。总之，仅当精子浓度不降至最佳值以下时，激肽释放酶才是治疗弱精子症的有效药物。